News by subject: TRI

Haystack Oncology, a Quest Diagnostics company, has entered into a collaboration with Alliance Foundation Trials, LLC (AFT) for research use of Haystack Oncology's personalized MRD technology (Haystack MRDtm) to analyze therapeutic response and...

The Partner of Biosion Inc. (Biosion) , OBI Pharma (4174.TWO), announced that the U.S. Food and Drug Administration (FDA) has cleared an investigational new drug (IND) application for OBI-992, to conduct a Phase 1/2...

Caliway Biopharmaceuticals (Caliway) announced that the United States Food and Drug Administration (U.S. FDA) has accepted the CBL-514 Investigational New Drug (IND) application of CBL-0202 DD Phase 2 Study to treat Dercum's Disease. Dercum's...

Akadeum Life Sciences?the global leader in buoyancy-based cell separation technology?has been selected to present on its revolutionary microbubble platform at this year's Biotech Showcase, which is being held from January 8-10 in San Francisco....

The article, titled "Salvage of...

Base4 Biotechnology (formerly known as Nymirum) today announced that it has expanded its license agreement with Servier to strengthen the companies' strategic collaboration to develop RNA-targeted small molecule therapeutics. This agreement leverages...

Today, Nature Medicine published the results of a clinical trial, in which 30 former Navy SEALs were administered ibogaine at Ambio Life Sciences in Mexico to treat traumatic brain injuries, which they developed during their military careers. The...

The American College of Clinical Pharmacology® (ACCP) published a recent Position Paper entitled "Hydration and Vitamin Infusion Clinics". Hydration and vitamin clinics, so-called "drip clinics", offer vitamin infusions (like vitamin B or C) and...

Avidity Biosciences, Inc. , a...

Endotronix, Inc., a digital health and medical technology company dedicated to advancing the treatment of heart failure (HF), today announced the submission of a Premarket Approval (PMA) application for its Cordellatm Pulmonary Artery (PA) Sensor...

Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing a new generation of biologic therapy to treat solid tumor cancers and chemotherapy-induced peripheral neuropathy (CIPN), announced today that the Company will present...

ProfoundBio, a clinical-stage biotechnology company developing novel antibody-drug conjugate (ADC) therapeutics for cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for rinatabart sesutecan...

Rivus Pharmaceuticals Inc., a clinical-stage biopharmaceutical company dedicated to improving cardiometabolic health, today announced the completion of enrollment in its Phase 2a HuMAIN trial of HU6, an investigational controlled metabolic...

Akeso (9926.HK) announced the China National Medical Products Administration (NMPA) has accepted the supplemental new drug application (sNDA) of cadonilimab (???®, PD-1/CTLA-4 bispecific antibody, AK104) in combination with capecitabine plus...

Elevation Oncology, Inc. , an innovative oncology company focused on the discovery and development of...

With thousands of press releases published each week, it can be difficult to keep up with everything on Cision. To help journalists and consumers stay on top of the week's most newsworthy and popular releases, here's a recap of some major stories...

Theravance Biopharma, Inc. today announced results from the Phase 4 PIFR-2 study of YUPELRI® (revefenacin) inhalation solution, the only once-daily, nebulized long-acting muscarinic antagonist (LAMA) approved in the U.S. for maintenance treatment of...

Vico Therapeutics B.V., a clinical-stage genetic medicines company developing therapies for severe neurological diseases,...

Aligned with the FDA on submitted protocol for 225Ac-PSMA (FPI-2265) Phase 2/3 registrational program for patients with metastatic castration-resistant prostate cancer (mCRPC)Achieved target enrollment in ongoing TATCIST trial evaluating FPI-2265;...

In a study designed to better understand sudden, unexpected deaths in young children, which usually occur during sleep, researchers have identified brief seizures, accompanied by muscle convulsions, as a potential cause....

A new study shows that lapatinib, a drug used for the treatment of metastatic HER2-positive cancer, is associated with improved overall survival in patients with initially HER2-negative metastatic breast cancer and HER2-positive circulating tumor...

The Association for Diagnostics & Laboratory Medicine's (formerly AACC's) Clinical Chemistry journal released a special issue today titled "Cancer: Biology and Diagnostics," which presents a wide range of discoveries with the potential to improve...

KAT6 is an emerging target in hormone sensitive breast tumors and other cancers. Overexpression of KAT6A/B correlates with poor clinical outcomes in patients with ER+/HER2- breast cancer ? the most common subtype.The molecule has demonstrated strong...

WCG, the global leader in providing solutions that measurably improve and accelerate clinical research, has unveiled its WCG Clinical Research Trends & Insights 2024 report. The report is curated by 12 preeminent thought leaders who are transcending...

G3 Therapeutics ("G3"), a global leader in the use of multiomic biological Big Data, has initiated a groundbreaking initiative to unravel the contribution of Lipoprotein(a) ["Lp(a)"] to cardiovascular disease (CVD). As the treatment of LDL...

Alamar Biosciences, a company powering precision proteomics to enable the earliest detection of disease, announced today the commercial launch of the ARGO HT System for push-button, high sensitivity analysis of proteins in biofluids and the NULISAseq...

Rigel Pharmaceuticals, Inc.  today announced a collaboration with CONNECT, an international collaborative network of pediatric cancer centers, to conduct a Phase 2 clinical trial to evaluate REZLIDHIA® (olutasidenib) in combination with temozolomide...

Avenzo Therapeutics, Inc. (Avenzo), a clinical-stage biotechnology company...

Cerapedics Inc., a commercial-stage orthopedics company dedicated to redefining the standard of care for bone repair, today announced that it has filed the final module in the Pre-Market Approval (PMA) application with the U.S. Food and Drug...

Reported positive early clinical data for allogeneic myeloma cell therapy P-BCMA-ALLO1 at ASH 2023 supporting potential of TSCM-rich allogeneic CAR-T to offer a differentiated and compelling efficacy, safety, and reliability profile that could...

Artax Biopharma, Inc., a clinical-stage biotechnology company focused on transforming the treatment of autoimmune diseases, today announces important...

INOVIO , a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer and infectious diseases, today announced a clinical collaboration and supply agreement with...

Human Immunology Biosciences (HI-Biotm), a clinical-stage biotechnology company developing targeted therapies for patients with severe immune-mediated diseases (IMDs), today announced the closing of a $95 million Series B financing led by new...

Soligenix, Inc. (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today preliminary top-line results of its...

Relmada Therapeutics, Inc. , a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today provided a corporate update, highlighted the Company's key 2023 accomplishments and outlined its...

Oncolytics Biotech® Inc. , a clinical-stage immunotherapeutics company focused on oncology, reported on significant 2023 accomplishments and announced corporate priorities and anticipated clinical development milestones for 2024. Overview: "2023...

Latest issue of The New England Journal of Medicine reports promising results in the treatment of Alzheimer's disease using focused ultrasound technology to disrupt blood-brain barrier Focused ultrasound temporarily opens up blood-brain barrier to...

Scinai Immunotherapeutics Ltd. , a biopharmaceutical company focused on development of inflammation and immunology (I&I) biological products, today published a letter from its CEO, Amir Reichman, addressing the Company's 2023 accomplishments,...

Alex Therapeutics and Vicore Pharma today announced positive results of the COMPANION study, investigating...

Medivir AB , a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announced today that Medivir's licensee, Tango Therapeutics , has dosed the first patient with TNG348, a novel USP1...

Laekna (2105.HK), a...

Kyverna Therapeutics, Inc. (Kyverna), a patient-centered clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune...

GPN Vaccines Ltd, a clinical-stage biotechnology company developing a Streptococcus pneumoniae vaccine to prevent life-threatening pneumonia, bacteraemia and meningitis, is pleased to announce positive safety and immunogenicity data from its Phase 1...

Driven by the need for a better way to prioritize targets for drug development, the Icahn School of Medicine at Mount Sinai has led the development of a novel "genetic priority score" (GPS) that will integrate various types of human genetic data into...

ChemDiv Inc, a leading provider of drug discovery platforms and development solutions, celebrates a significant milestone in collaboration with Orionis Biosciences: the commencement of Phase I clinical trials for ORB-011, a cutting-edge attenuated,...

Vitti Labstm, an AATB accredited tissue bank and life sciences company based in Liberty, MO, announced today that VL-PX10 and VL-P22, a first in class combination cellular therapy with umbilical cord Mesenchymal Stem Cell Exosomes, and Mesenchymal...

Extended-release ML-007 was evaluated for safety, tolerability, and pharmacokinetic profile in healthy volunteers across several dosing regimens, alone and when co-administered with an extended-release muscarinic antagonistExtended-release ML-007 was...

AbelZeta Pharma, Inc. ("AbelZeta" or the "Company"), a global clinical-stage biopharmaceutical company focused on discovery and development of innovative and proprietary cell-based therapeutic products, today announced the formation of a Scientific...

Octapharma USA has announced Balfaxar® (prothrombin complex concentrate, human-lans; marketed in Europe and Canada as octaplex®) is now available. The new non-activated four factor prothrombin complex concentrate (4F-PCC), approved by the U.S. Food...

In rare disease research, companies like IndoUSRare are exploring effective strategies such as establishing clinical research sites in countries with a higher incidence of specific rare diseases. This approach, coupled with the utilization of...